Both moderate and severe COVID-19 patients were characterized by the progressive expansion of CD16 neutrophils, which also expressed lower levels of CD177, CD11b, and CD62L and higher levels of CD66b and LOX-1, a phenotype compatible with neutrophil immaturity. Here, CD177 is linked to COVID-19.